Clomipramine

Clomipramine is a tricyclic antidepressant, a family of drugs named for the three-ring core of their chemical structure ^[1]. It was created as a chlorinated derivative of imipramine, and among the tricyclics it stands out for its unusually strong effect on the neurotransmitter serotonin ^[1][2]. In the body it is broken down in the liver into an active metabolite, desmethylclomipramine, that leans more toward acting on noradrenaline; both the parent drug and this metabolite contribute to its effects, and both persist long enough that steady blood levels take a couple of weeks to establish ^[3].

The compound was developed by the Swiss company Geigy, was first described in the scientific literature in the early 1960s, and reached the market in Western Europe as an antidepressant, where it became well established, particularly for depression that had resisted other treatments ^[2][3]. In the United States it followed a different path: rather than being cleared for depression, it was approved in 1989 for obsessive-compulsive disorder and became available the following year, and to this day it carries a US licence for OCD rather than for depression ^[1][2].

Clomipramine's best-documented strength is in obsessive-compulsive disorder, where controlled trials found it more effective than several other tricyclics at reducing obsessions and compulsions, an anti-obsessional benefit that appears to be separate from its antidepressant action ^[2]. It is also used to treat major depression and panic disorder, in which it lessens the frequency and severity of panic attacks, and it is prescribed for cataplexy in narcolepsy ^[2]. Off-label and additional uses include premature ejaculation, chronic pain, trichotillomania and body dysmorphic disorder ^[1].

Because it blocks several receptor systems beyond its reuptake action, clomipramine produces a broad set of predictable side effects, many of them anticholinergic, such as dry mouth, constipation, blurred vision and drowsiness, along with weight gain, tremor and sexual difficulties ^[2]. Seizures are a recognised dose-related risk that becomes more frequent at higher doses, and like other tricyclics it can disturb the heart's electrical conduction and is dangerous in overdose ^[2]. As with other antidepressants, it carries a warning about a possible increase in suicidal thoughts in people under twenty-five, and its behaviour in special situations such as pregnancy has been studied because both it and its active metabolite cross into the circulation ^[2][4].

Clomipramine is a prescription-only medicine, is available as an inexpensive generic, and is listed on the World Health Organization Model List of Essential Medicines; it is usually taken as oral capsules or tablets ^[1][2].

Same tricyclic caution as the rest: cardiotoxic in overdose, so a narrow safety margin. It lowers the seizure threshold more than most, so seizures are a real consideration at higher amounts. Common sides are dry mouth, constipation, sweating, weight gain, drowsiness, and sexual dysfunction. Never combine with MAO inhibitors. Prescription only.

Clomipramine is metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, making its exposure sensitive to genetic variation and to drugs that inhibit these enzymes. Patients who are CYP2D6 poor metabolizers need dose reductions to 50% of the normal dose when treated for depression, or when side effects occur at normal doses for other indications; ultra-rapid metabolizers may need dose increases to 1.5 times the normal dose. For clomipramine prescribed for anxiety or obsessive-compulsive disorder in CYP2C19 ultra-rapid metabolizers, alternative medications may be needed ^[23].

Other SSRIs and tricyclic antidepressants can competitively inhibit these same enzymes, leading to phenoconversion (a change in metabolizer status during treatment). This mechanism is pharmacokinetic; the co-medication reduces clomipramine clearance and raises its levels. The combination of clomipramine with drugs like fluoxetine or paroxetine, which are potent CYP2D6 inhibitors, should be approached with caution, though specific clinical outcomes from this pairing are underreported.

Clomipramine's interactions with most other drug classes remain unstudied. Interactions with non-psychiatric medications, most antibiotics, and antihistamines are not documented in clinical trials.

Checking a whole stack? Run it through interactions + stacks.